Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives

Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Drago, 2021, Unlocking the potential of antibody–drug conjugates for cancer therapy, Nat Rev Clin Oncol, 18, 327, 10.1038/s41571-021-00470-8 Verma, 2012, Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124 Tarantino, 2022, Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies, CA Cancer J Clin, 72, 165, 10.3322/caac.21705 Robert, 2020, A decade of immune-checkpoint inhibitors in cancer therapy, Nat Commun, 11, 3801, 10.1038/s41467-020-17670-y Robert, 2018, Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma, J Clin Oncol, 36, 1668, 10.1200/JCO.2017.75.6270 Sharma, 2017, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 Jenkins, 2018, Mechanisms of resistance to immune checkpoint inhibitors, Br J Cancer, 118, 9, 10.1038/bjc.2017.434 Salas-Benito, 2021, Paradigms on immunotherapy combinations with chemotherapy, Cancer Discov, 11, 1353, 10.1158/2159-8290.CD-20-1312 Lake, 2005, Immunotherapy and chemotherapy — a practical partnership, Nat Rev Cancer, 5, 397, 10.1038/nrc1613 Ménétrier-Caux, 2019, Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?, J Immunother Cancer, 7, 85, 10.1186/s40425-019-0549-5 Gerber, 2016, Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?, Biochem Pharmacol, 102, 1, 10.1016/j.bcp.2015.12.008 Tiller, 2015, Advances in Antibody Design, Annu Rev Biomed Eng, 17, 191, 10.1146/annurev-bioeng-071114-040733 Yu, 2020, How to select IgG subclasses in developing anti-tumor therapeutic antibodies, J Hematol Oncol, 13, 45, 10.1186/s13045-020-00876-4 Vidarsson, 2014, IgG Subclasses and Allotypes: From Structure to Effector Functions, Front Immunol, 5, 10.3389/fimmu.2014.00520 Hoffmann, 2018, Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs), Oncoimmunology, 7, e1395127, 10.1080/2162402X.2017.1395127 Ogitani, 2016, DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1, Clin Cancer Res, 22, 5097, 10.1158/1078-0432.CCR-15-2822 Junttila, 2011, Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer, Breast Cancer Res Treat, 128, 347, 10.1007/s10549-010-1090-x Uppal, 2015, Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1), Clin Cancer Res, 21, 123, 10.1158/1078-0432.CCR-14-2093 Tai, 2014, Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma, Blood, 123, 3128, 10.1182/blood-2013-10-535088 Beck, 2012, Marketing approval of mogamulizumab: A triumph for glyco-engineering, MAbs, 4, 419, 10.4161/mabs.20996 Vafa, 2014, An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations, Methods, 65, 114, 10.1016/j.ymeth.2013.06.035 Pegram, 2021, First-in-Human, Phase 1 dose-escalation study of Biparatopic Anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer, Mol Cancer Ther, 20, 1442, 10.1158/1535-7163.MCT-20-0014 Li, 2017, Tumor-associated macrophages can contribute to antitumor activity through FcγR-mediated processing of antibody-drug conjugates, Mol Cancer Ther, 16, 1347, 10.1158/1535-7163.MCT-17-0019 Garg, 2015, Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death, Front Immunol, 6, 10.3389/fimmu.2015.00588 Kroemer, 2013, Immunogenic Cell Death in Cancer Therapy, Annu Rev Immunol, 31, 51, 10.1146/annurev-immunol-032712-100008 Ahmed, 2020, Targeting immunogenic cell death in cancer, Mol Oncol, 14, 2994, 10.1002/1878-0261.12851 Galluzzi, 2018, Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018, Cell Death Differ, 25, 486, 10.1038/s41418-017-0012-4 Kepp, 2014, Consensus guidelines for the detection of immunogenic cell death, Oncoimmunology, 3, e955691, 10.4161/21624011.2014.955691 Sukkurwala, 2014, Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set, Oncoimmunology, 3, e28473, 10.4161/onci.28473 Rios-Doria, 2015, Doxil Synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models, Neoplasia, 17, 661, 10.1016/j.neo.2015.08.004 Galluzzi, 2012, The secret ally: immunostimulation by anticancer drugs, Nat Rev Drug Discov, 11, 215, 10.1038/nrd3626 Liu, 2015, The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4, Clin Cancer Res, 21, 1639, 10.1158/1078-0432.CCR-14-2339 Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat Med, 13, 54, 10.1038/nm1523 Voorwerk, 2019, Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial, Nat Med, 25, 920, 10.1038/s41591-019-0432-4 Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356 Bauzon, 2019, Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells, Oncoimmunology, 8, e1565859, 10.1080/2162402X.2019.1565859 Rios-Doria, 2017, Antibody-drug conjugates bearing Pyrrolobenzodiazepine or Tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies, Cancer Res, 77, 2686, 10.1158/0008-5472.CAN-16-2854 D’Amico, 2019, A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer, J Immunother Cancer, 7, 10.1186/s40425-018-0464-1 Cao, 2017, Abstract 5588: Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo. Immunology, Am Assoc Cancer Res, 5588, 10.1158/1538-7445.AM2017-5588 Cao, 2018, Abstract 2742: Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Immunology, American Association for, Cancer Res, 2742, 10.1158/1538-7445.AM2018-2742 Boshuizen, 2021, Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade, Cancer Res, 81, 1775, 10.1158/0008-5472.CAN-20-0434 Wculek, 2020, Dendritic cells in cancer immunology and immunotherapy, Nat Rev Immunol, 20, 7, 10.1038/s41577-019-0210-z Hargadon, 2013, Tumor-altered dendritic cell function: implications for anti-tumor immunity, Front Immunol, 4, 10.3389/fimmu.2013.00192 Martin, 2014, The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity, Cancer Immunol Immunother, 63, 925, 10.1007/s00262-014-1565-4 Tanaka, 2009, Dual Therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation, Cancer Res, 69, 6987, 10.1158/0008-5472.CAN-09-1106 Müller, 2014, Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells, Cancer Immunol Res, 2, 741, 10.1158/2326-6066.CIR-13-0198 Müller, 2015, Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade, Sci Transl Med, 7, 10.1126/scitranslmed.aac4925 Tanaka, 2009, Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells, Cancer Res, 69, 6978, 10.1158/0008-5472.CAN-09-1101 Iwata, 2018, A HER2-targeting antibody-drug conjugate, Trastuzumab Deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model, Mol Cancer Ther, 17, 1494, 10.1158/1535-7163.MCT-17-0749 Nicolò, 2020, Antibody–drug conjugates in breast cancer: the chemotherapy of the future?, Curr Opin Oncol, 32, 494, 10.1097/CCO.0000000000000656 Savas, 2016, Clinical relevance of host immunity in breast cancer: from TILs to the clinic, Nat Rev Clin Oncol, 13, 228, 10.1038/nrclinonc.2015.215 Stagg, 2011, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, Proc Natl Acad Sci, 108, 7142, 10.1073/pnas.1016569108 Akiyama, 2003, Targeting Apoptotic Tumor Cells to FcγR Provides Efficient and Versatile Vaccination Against Tumors by Dendritic Cells, J Immunol, 170, 1641, 10.4049/jimmunol.170.4.1641 Varchetta, 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under Trastuzumab therapy for primary operable breast cancer overexpressing Her2, Cancer Res, 67, 11991, 10.1158/0008-5472.CAN-07-2068 Su, 2018, Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages, Cell, 175, 442, 10.1016/j.cell.2018.09.007 Emens, 2018, Breast cancer immunotherapy: facts and hopes, Clin Cancer Res, 24, 511, 10.1158/1078-0432.CCR-16-3001 Emens, 2020, Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, Lancet Oncol, 21, 1283, 10.1016/S1470-2045(20)30465-4 Hamilton, 2020, Am Assoc Cancer Res, PD1-05., 10.1158/1538-7445.SABCS19-PD1-05 Waks, 2020, A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC), J Clin Oncol, 38, 1046, 10.1200/JCO.2020.38.15_suppl.1046 Hamilton, 2021, Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study. Poster Spotlight Sess. Abstr., Am Assoc Cancer Res, PD3-07., 10.1158/1538-7445.SABCS20-PD3-07 Borghaei, 2020, Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study, J Clin Oncol, 38, TPS1100, 10.1200/JCO.2020.38.15_suppl.TPS1100 Bianchini, 2022, Treatment landscape of triple-negative breast cancer — expanded options, evolving needs, Nat Rev Clin Oncol, 19, 91, 10.1038/s41571-021-00565-2 Schmid, 2021, BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd), J Clin Oncol, 39, 1023, 10.1200/JCO.2021.39.15_suppl.1023 Han H (Heather), Diab S, Alemany C, Basho R, Brown-Glaberman U, Meisel J, et al. Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. Poster Spotlight Sess. Abstr., Am Assoc Cancer Res; 2020:PD1-06. https://doi.org/10.1158/1538-7445.SABCS19-PD1-06. Powles, 2021, Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, N Engl J Med, 384, 1125, 10.1056/NEJMoa2035807 Powles, 2020, Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, N Engl J Med, 383, 1218, 10.1056/NEJMoa2002788 Friedlander, 2021, Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC), J Clin Oncol, 39, 4528, 10.1200/JCO.2021.39.15_suppl.4528 Sheng, 2019, A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma, J Clin Oncol, 37, 4509, 10.1200/JCO.2019.37.15_suppl.4509 Zhou, 2022, Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma, J Clin Oncol, 40, 515, 10.1200/JCO.2022.40.6_suppl.515 Galsky, 2022, Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC), J Clin Oncol, 40, 438, 10.1200/JCO.2022.40.6_suppl.438 Tagawa, 2021, TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors, J Clin Oncol, 39, 2474, 10.1200/JCO.20.03489 National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 1.2022). n.d. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed January 24, 2022). National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 2.2022). n.d. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf . (accessed January 24, 2022). Desai, 2022, Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer, Lung Cancer, 163, 96, 10.1016/j.lungcan.2021.12.002 Li, 2022, Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer, N Engl J Med, 386, 241, 10.1056/NEJMoa2112431 Jänne, 2022, Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer, Cancer Discov, 12, 74, 10.1158/2159-8290.CD-21-0715 Spira, 2021, OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study, J Thorac Oncol, 16, S106, 10.1016/j.jtho.2021.01.280 Camidge, 2022, A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC, JTO Clin Res Reports, 3, 100262, 10.1016/j.jtocrr.2021.100262 Malhotra, 2021, A Phase 1–2 Study of Rovalpituzumab Tesirine in combination with Nivolumab plus or minus Ipilimumab in patients with previously treated extensive-stage SCLC, J Thorac Oncol, 16, 1559, 10.1016/j.jtho.2021.02.022 Matulonis, 2018, Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study, Ann Oncol, 29, viii339, 10.1093/annonc/mdy285.157 Saini, 2021, Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics, Expert Opin Biol Ther, 21, 945, 10.1080/14712598.2021.1936494 Rabinovich, 2007, Immunosuppressive Strategies that are Mediated by Tumor Cells, Annu Rev Immunol, 25, 267, 10.1146/annurev.immunol.25.022106.141609 Russ, 2011, Suppression of T-Cell Expansion by Melanoma is Exerted on Resting Cells, Ann Surg Oncol, 18, 3848, 10.1245/s10434-011-1667-6 Puré, 2016, Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?, Cancer Immunol Res, 4, 269, 10.1158/2326-6066.CIR-16-0011 Zou, 2016, PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations, Sci Transl Med, 8, 10.1126/scitranslmed.aad7118 Emens, 2015, The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies, Cancer Immunol Res, 3, 436, 10.1158/2326-6066.CIR-15-0064 Sau, 2019, PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer, Cancers (Basel), 11, 232, 10.3390/cancers11020232 Scribner, 2020, Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7–H3 for Solid Cancer, Mol Cancer Ther, 19, 2235, 10.1158/1535-7163.MCT-20-0116 Jang, 2021, Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors, J Clin Oncol, 39, 2631, 10.1200/JCO.2021.39.15_suppl.2631 Moyes, 2019, Abstract 3271: A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors, Immunol Am Assoc Cancer Res, 3271 Ackerman, 2021, Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity, Nat Cancer, 2, 18, 10.1038/s43018-020-00136-x Ackerman, 2019, Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models. Immunology, American Association for, Cancer Res, 1559, 10.1158/1538-7445.AM2019-1559 Cristofaro, 2003, The Toll-like receptors and their role in septic shock, Expert Opin Ther Targets, 7, 603, 10.1517/14728222.7.5.603 Knuefermann, 2002, Cardiac Inflammation and Innate Immunity in Septic Shock, Chest, 121, 1329, 10.1378/chest.121.4.1329 Sharma, 2020, 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors, J Immunother Cancer, 8, A426 Sharma, 2021, Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, J Clin Oncol, 39, 2549, 10.1200/JCO.2021.39.15_suppl.2549 Klempner, 2021, 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors, Ann Oncol, 32, S450, 10.1016/j.annonc.2021.08.491 He, 2021, Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy, J Med Chem, 64, 15716, 10.1021/acs.jmedchem.1c00961 Vasan, 2019, A view on drug resistance in cancer, Nature, 575, 299, 10.1038/s41586-019-1730-1